Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 5/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | HPD | P32754 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22129300 | 1.00 | HCAR3 (0.39) | HCAR3PIM1SMN1; SMN2LMNAHTT | |
| SCHEMBL22129301 | 1.00 | HCAR3 (0.39) | HCAR3PIM1SMN1; SMN2LMNAHTT | |
| SCHEMBL22129296 | 0.89 | HCAR3 (0.38) | HCAR3SMN1; SMN2LMNAHTTKMT2A | |
| SCHEMBL29743229 | 0.89 | HCAR3 (0.38) | HCAR3SMN1; SMN2LMNAHTTKMT2A | |
| SCHEMBL29743215 | 0.89 | HCAR3 (0.38) | HCAR3SMN1; SMN2LMNAHTTKMT2A | |
| SCHEMBL22129297 | 0.89 | HCAR3 (0.38) | HCAR3SMN1; SMN2LMNAHTTKMT2A | |
| SCHEMBL21522752 | 0.85 | HCAR3 (0.36) | HCAR3LMNAKMT2AMEN1GAA | |
| SCHEMBL29788706 | 0.82 | LMNA (0.39) | HCAR3SMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL20600834 | 0.82 | LMNA (0.39) | HCAR3SMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL18152724 | 0.81 | HCAR3 (0.47) | HCAR3SMN1; SMN2LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017520-A1 | MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3865488-A1 | MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017520-A1 | MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | CDK4, CDK7, CDKL1 | HCAR3 4239/4885PIM1 80/4885SMN1; SMN2 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.